Citadel Advisors LLC Purchases New Stake in Portage Biotech Inc. (NASDAQ:PRTG)

Citadel Advisors LLC purchased a new stake in Portage Biotech Inc. (NASDAQ:PRTG) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 15,431 shares of the company’s stock, valued at approximately $80,000.

Portage Biotech Stock Performance

Shares of Portage Biotech stock opened at $7.78 on Wednesday. The firm has a market capitalization of $8.16 million, a price-to-earnings ratio of -0.19 and a beta of 0.33. Portage Biotech Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $23.01. The stock has a 50 day moving average of $8.08 and a 200 day moving average of $5.90.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.